Skip to main content
. Author manuscript; available in PMC: 2023 Jun 10.
Published in final edited form as: Nature. 2018 Jul 18;560(7716):55–60. doi: 10.1038/s41586-018-0342-5

Extended Data Figure 9: Anti-α6 integrin blocking antibody treatment prolongs survival, but does not alter disease burden in the BM or spleen of Nalm-6 leukemic mice.

Extended Data Figure 9:

a, α6 integrin neutralizing antibody treatment schema. b, Kaplan-Meier survival curves for Nalm-6 mice treated +/− anti-integrin-α6 blocking antibodies (two-sided log rank Mantel-Cox, n = 3 mice per treatment group, P=0.0224). c-d, Disease burden at endpoint in the BM and spleen of vehicle and anti-integrin α6 antibody-treated Nalm-6 leukemic mice (mean ± s.e.m., paired two-sided Student’s t-test, n = 3 mice per treatment group, P = 0.7874 (BM), P = 0.1595 (spleen)).